Kinesin Spindle Protein Inhibitor Kills Blood Cancers and Solid Tumors with Dr. Ahmed Hamdy Vincerx

Dr. Ahmed Hamdy, CEO and Co-Founder of Vincerx, is focused on targeting a specific antigen found on cancer cells. With a unique enzyme, it is effective with solid tumors and hematological malignancies, releasing a kinesin spindle protein inhibitor that inhibits the division of cancer cells. Their first bioconjugate VIP236 targets a specific molecule expressed on several metastatic tumors. Ahmed explains, "At Vincerx, we have a very exciting pipeline that's designed to solve a lot of problems with the current treatments for cancer therapies. In today's world, cancer continues growing exponentially. And thankfully, there are a lot of treatments out there for different types of cancer. Yet, the current treatments come with quite a bit of morbidities. Throughout my career, the morbidity of medicine has been something that I've always been concerned about, especially for patients and their caregivers. At Vincerx, we have very exciting, unique types of treatments that can be paradigm-shifting from a safety perspective and efficacy perspective." "For solid tumors, we have a compound that's currently in dose escalation phase 1 trial that is designed for advanced metastatic tumors, where we target a specific antigen that is found on the cancer cells themselves. And with a unique enzyme, it cleaves what we're describing as a warhead or the substance that can kill the cancer cell, which is an optimized camptothecin. And the word optimize means it's a well-known topoisomerase inhibitor designed to allow for very rapid permeability or intake by the cancer cell, with very low pumping out." #VincerxPharma #VIP236 #VIP943 #ADCs #Bioconjugates #Cancer #SolidTumors #Biotech #PrecisionMedicine Vincerx.com Download the transcript here